Pankreas-Studien
| Neonax |
|---|
| Neoadjuvant plus adjuvant or only adjuvant nab-Paclitaxel plus Gemcitabine for resectable pancreatic cancer |
|
Ansprechpartner: Prüfer: Prof. Gress Studiensekretariat: E. Kort, F. Trebes-Börner |
| Alpaca |
|---|
| Inducation treatment with nab-Paclitaxel/Gemcitabine for first-line treatment of metastatic pancreatic cancer followed by either alternating application of Gemcitabine monotherapy and nab- Paclitaxel/Gemcitabine or continuing apllication of nab-Paclitaxel/Gemcitabine: a andomized phase II study confidentiality statement |
|
Ansprechpartner: Studiensekretariat: E. Kort, F. Trebes-Börner |
| Predict |
|---|
|
Second line therapy with NaI-IRI after failure gemcitabine/nab-paclitaxel in advanced cancer predictive role of first line therapy Ansprechpartner: Studiensekretariat: E. Kort, F. Trebes-Börner |
| META-PAC |
|---|
| Prospektive Studie zum Plasma-Metabolom Multimarker Panel MxP® PancreasScore zum Ausschluss eines Pankreaskarzinoms in Risikokohorten |
|
Ansprechpartner: Studiensekretariat: E. Kort, F. Trebes-Börner |